EUROPEAN JOURNAL OF BIOMEDICAL AND PHARMACEUTICAL SCIENCES
http://www.ejbps.com

ISSN 2349-8870
Volume: 11
Issue: 7
225-230
Year: 2024

PHARMACOLOGICAL EVALUATION, SYNTHESIS AND CHARACTERIZATION OF mTOR INHIBITORS FOR ANTICANCER ACTIVITY

Prateek Porwal*, Shailendra singh, Ankita Singh Dhakrey, Priya Bhardwaj, Lakhan, Toni Shah

FS College of Pharmacy and Research Centre, FS University, Near Balaji Mandir, Shikohabad - 283125, Uttar Pradesh, India.

***Corresponding Author: Prateek Porwal**
Assistant Professor, FS College of Pharmacy and Research Centre, FS University, Near Balaji Mandir, Shikohabad - 283125, Uttar Pradesh, India.

Article Received on 20/05/2024 **Article Revised on 10/06/2024** **Article Accepted on 30/06/2024**

ABSTRACT
Cancer can be characterize as a sickness where a get-together of strange cells develop broadly by ignoring the typical standard of cell division. About one out of every three people develop cancer. Every quality and every cell division results in one in twenty million DNA changes occurring on a regular basis.. The ordinary number of cells outlined in any individual during a common lifetime is 1016 (10 million cells being displaced reliably!). The chance of malignant growths is extended by irresistible specialists, with infections [Hepatitis B infection (HBV1), Human Papillomavirus (HPV), Human Immunodeficiency Virus (HIV)- increment hazard of Pharyngeal, Cervical carcinoma, and Kaposi's Sarcoma] and microorganisms like H-pylori (stomach diseases). Up-and-comer atoms be docking for anticancer action target mTOR utilizing molecule plan programming. 25 platforms was screen with a high docking attain beside mTOR inhibitors. These mixtures likewise accepted Lipinski's standard. Quinoline nucleus-containing scaffold were chosen for its synthetic viability.

KEYWORDS: Combination, anticancer action, DNA transformations, mTOR inhibitor.

INTRODUCTION
Cancer can be characterize as a sickness where a get-together of strange cells develop broadly by ignoring the typical standard of cell division. About one out of every three people develop cancer. DNA transformations arise consistently at a repeat of 1 in every 20 million for each quality for every cell division. Typical quantity of cells framed in several individual during typical life is 1016 (10 million cells being supplant consistently!). The chance of malignant dangerous developments is extended including contaminations [Hepatitis B contamination (HBV1), Human Papillomavirus (HPV), Human Immunodeficiency Infection (HIV)- increase peril of Nasopharyngeal, Cervical carcinomas, and Kaposi's Sarcoma] and microorganisms like H-pylori (stomach sicknesses). Inception and progress of disease are moreover a result of openness to malignant expansion causing specialists (mutagens carcinogen-causing agents,). They are found in the water, air. Food and synthetic substances and daytime those are present too. Since epithelial cells cover line the respiratory, the skin, and nutritious parcels, and use ingested malignant growth causing specialists, it is not actually to be expected that over 90% of disease start from epithelia (carcinomas). A hereditary inclination expands the risk of malignancy growing a whole lot sooner in under 10% of cases. Cancers of the retina, certain childhood leukemias, and others Despite the actuality that malignant growth can arise in populace of each and all age, it is typical with the developing people. 60% of new sickness cases and 66% of malignant growth passings occur in individuals >65 years. Age is related with an increased risk of general cancer like breast cancer, colorectal cancer, prostate cancer, and lungs cancer. The outstanding ascent in numerous malignant growths with age fits with an expanded weakness to the delayed phases of cancer by ecological openings. Breast or uterine cancer can result from long-term estrogen exposure, while prostate cancer results from testosterone exposure. The decrease in cell resistance may likewise prompt particular sorts of disease that are exceptionally immunogenic (for example, lymphomas and melanomas). To be considered cancer, the accumulation of DNA mutations must be increased, so the risk of developing cancer increases with age.

These are the six symptoms of cancer
Immortality is the unstoppable division and replication of cells.
• Produce "Go" signals (oncogene-derived growth factors)

• Supersede 'Stop' signals (against development signals from cancer silencer qualities)
• Protection from cell demise (apoptosis)
• Angiogenesis: the development of new blood vessels
• Metastasis: Spread to different destinations



Fig.1 Structure of Normal and cancer cells.

Types of cancer

Tumors might be classified in light of the capabilities/areas of the cells that they start. The accompanying terms are generally used to sort by their tissue of beginning.

- Formation of antibodies (B lymphocytes or B-cells)⎤ Carcinoma-a development that comes from epithelial cells, those cells that present outer layer of our organs and skin. It is the mainly recognized malignant growth type and addresses around 80-90% of the entire disease cases announced.
- Sarcoma, a tumor that originates from connective tissue, muscle, bone, or cartilage;
- Leukemia, a cancer that starts in WBC or in their precursor. The cells that structure both white and red platelets are located in the bone marrow.
- Lymphoma, a lymphatic system-affecting cancer that originates in the bone marrow.
- Myelomas-a malignant growth including the white platelets liable for the (B-cells or B lymphocytes) antibodies production.

Every kind of disease is remarkable with its some causes, side effects, and strategy for cure. The mainly well-known malignant growths are:

Cancer of the breast

- Colorectal malignant growth Carcinoma
- Cellular breakdown in the lungs Carcinoma
- Prostate disease Carcinoma
- Skin malignant growth Carcinoma
- Bladder malignant growth Carcinoma
- Renal cell carcinoma
- Pancreatic disease Carcinoma
- Lymphoma

All around the world, disease of the colon and rectum[5, 6,7] is the third driving reason for malignant growth in guys and fourth driving reason for disease in females. The recurrence of colorectal malignant growth changes all over the planet. It is normal in the western countries and is infrequent in Africa and Asia. In nations somewhere individuals have embraced western weight control plans, the rate of colorectal disease is expanding. High levels of lipid intake, a family background of colorectal malignant growth and polyps, the presence of polyps in the large intestine, and chronic ulcerative colitis are all hazard factors for colorectal malignant growth.

The different receptor targets for cancer growth are as per the following

- mTOR Receptors
- EGFR Receptor
- PDGF Receptor
- Adenosine Receptor
- Estrogen Receptor
- GPCR Receptor
- Chemokines Receptor
- CDK Receptor
- CB(1) Receptor
- FGF Receptor
- IGF Receptor
- HGF Receptor
- IFN Receptor

mTOR Receptors is an intracellular kinase that phosphorylates translational machinery to regulate the synthesis of several proteins.[8,9,10,11], Several characteristics of cancer, including angiogenesis, bioenergetics, and cell growth and proliferation, are facilitated by mTOR-activated proteins. Because many mutations observed in cancer frequently act as a neoplastic switch, inhibiting mTOR may be a viable new approach to cancer therapy.



Fig. 2: mTOR signaling pathway.

PI3K-related serine/threonine kinase phosphatidylinositol 3-kinase (mTOR) is sometimes referred to as FKBP 2-rapamycin associated protein (FRAP) or mammalian target of rapamycin (mTOR). It is a key player in a pathway that controls angiogenesis as well as cell growth, propagation, motility, and survival. Growth factors and mitogenic stimulation activate the phosphatidylinositol 3-kinase (PI3K)/AKt signaling pathway, which is one of the most commonly dysregulated pathways in cancer. This essential regulation of cell growth and proliferation is triggered. Research has demonstrated the involvement of this pathway in the advancement of prostate cancer and its shift towards an androgen-independent condition. The bacterial product rapamycin, a recognized mTOR inhibitor, was first discovered to have antifungal effects. It was later discovered to possess antiproliferative and immunosuppressive qualities. The drug rapamycin was found to have antitumor characteristics while it was being studied as an immunosuppressive agent to avoid organ rejection in transplant patients. In instance, endometrial cancer, renal cell carcinoma, and mantle cell lymphoma are among the cancer types against which rapamycin exhibits promise.

Modeling of Homology

The final aim of protein demonstrating is to accurately construction from its succession precisely, matching or exceeding the best experimental results. If experimental methods fail, the only way to gain structural information is through protein modeling. A lot of proteins are just too big to analyze using NMR and too big to crystallize for X-ray diffraction.

The multi-step process of homology modeling can be distilled into these seven steps

1. Initial alignment and template identification
2. Adjusting alignment
3. Generation of backbone
4. Modeling in loops
5. Model optimization;
6. Side-chain modeling
7. Validation of the model

Drug discovery[16,17,18]

Restorative science mixes engineered science, sub-atomic demonstrating, computational science, primary genomics and pharmacology to find and configuration new medications, and explore their communication at the atomic, cell and entire creature level. It combine rational design optimization of known drugs with empirical knowledge of their structure-function relationships with rational design optimization of drug molecules' physiochemical properties.

The course of medication revelation includes the recognizable proof of applicant particles, amalgamation, portrayal, evaluating for restorative viability and poisonousness studies. High-throughput screening (HTS), in which huge libraries of synthetic compounds are tried for their capacity to change the objective target, is typically used to find a novel drug that targets a specific disease target.

The two primary ways to deal with drug revelation and improvement are physiology-based drug disclosure and target-based revelation. The time span at which the medication target is really distinguished is where these two paradigms differ most.

Drug based on Physiology disclosure follows physiological readouts, for instance, the enhancement of an illness aggregate in a creature model or cell-based examine. A simply drug based on Physiology approach would at first swear off target ID/approval and on second thought hop directly into screening. In light of the particular pharmacological properties of lead compounds, the medication target and component of activity still up in the air in later phases of the cycle. Paradoxically, the street of target-based drug revelation starts with distinguishing the capability of a potential remedial objective and its job in sickness. One method

for finding promising medication applicants is to research how the objective protein connects through haphazardly picked compounds. This is finished by utilizing compound libraries which can include in excess of 1,000,000 engineered and regular mixtures. The target protein is then compared to these libraries. This is most frequently finished in alleged high-throughput screening offices. Hits are the compounds that exhibit binding activity and are the most promising compounds that are obtain through the selection process. After that, some of these hits are moved on to lead compound-candidate structures, where they are more developed and modified to get better interactions with fewer side effects. Computer-aided drug design (CADD) and structure-based drug design (SBDD) are important tools for drug discovery thanks to advancements in X-ray crystallography and NMR structure determination as well as computing power.

The following are the principal benefits of computational strategies over wet-lab tests:

- Small expenses, no mixtures must be bought remotely or combined by a physicist.
- It is feasible to research intensifies that poor person be integrated at this point.
- Leading high-throughput screening (HTS) tests.
- Virtual selection (Versus) can be utilized to lessen the underlying number of mixtures prior to utilizing high-Throughput Screening (HTS) techniques.
- Enormous synthetic inquiry space. The number of compounds currently existing for HTS is too lower than number of possible virtual molecules for VS.

CADD of lead compounds

A definite information on an objective restricting site essentially supports the plan of fresh lead compounds expected to tie with an objective. In cases, where compounds or receptors can be solidified, deciding the construction of the protein and its limiting site by X-beam crystallography is conceivable. Sub-atomic displaying programming can then be utilized to concentrate on the limiting site, and to plan particles which will fit and tie to the site-again drug plan. Now and again, the compounds or receptor can't be solidified thus X-beam crystallography can't be done. Notwithstanding, in the event that the design of a practically equivalent to protein not set in stone, this can be utilized as the reason for creating a PC model of the protein (Homology Displaying). Homology Demonstrating depends on the distinguishing proof of at least one realized protein structures liable to look like the construction of the question arrangement, and on the creation of an arrangement that maps deposits in the inquiry grouping to buildups in the layout succession. The succession arrangement and format structure that use to create an underlying model of the objective. The nature of the model is subject to the nature of the grouping arrangement and format structure.

Lipinski's standard of five19 is a guideline to assess drug resemblance or decide whether a substance compound with a specific pharmacological or natural action has properties that would formulate it a logical orally dynamic medication in people. The standard is significant for drug improvement wherever a pharmacologically dynamic lead structure is upgraded step-wise for expanded movement and selectivity, while as medication prefer properties as depicted by Lipinski's standard.

- Molecular weights below 500
- Not more than five donor groups for hydrogen bonds
- Not more than ten acceptor groups for hydrogen bonds
- A determined logP esteem under +5 (logP is a proportion of a medication's lipophilicity)

Molecular docking[20,21]

Sub-atomic docking program attempt to foresee how a medication competitor ties to a protein focus not including playing out a research facility try. Sub-atomic docking programming comprises of two center parts.

- An algorithm for searching (also known as an optimization algorithm). The inquiry calculation is answerable for tracking down the finest adaptations of the ligand and protein framework. A compliance is the site and direction of the ligand comparative with the protein. In adaptable docking, a compliance likewise contain data in relation to the inward adaptable construction of the ligand and at times in relation to the interior adaptable design of the protein. while the quantity of potential compliances is very enormous, it is unimaginable to expect to check every one of them, subsequently refined search methods must be useful. Genetic Algorithms and Monte Carlo Simulations are two examples of some common approaches.
- An assessment capability (in some cases called a score capability). A function called this tells how powerfully a ligand will interrelate with a specific protein. power force field are frequently utilized as assessment capabilities. These power fields compute the power commitment from various terms, for example, the known electrostatic powers between the particles in the ligand and in the protein powers emerging from misshapening of the ligand, unadulterated electron-shell aversion among molecules and impact from the dissolvable in which the connection happens.

Pharmacophore mapping

Pharmacophore mapping is an approach based on geometry. A pharmacophore is essentially a three-dimensional representation of the distinctive features of the protein's limiting site under study. It can likewise be considered a layout, an incomplete portrayal of a particle where certain spaces should be filled. Like Quantitative structure activity relationship models, lead molecule can be worked without significant design of the objective. This should be possible by separating highlights from

intensifies which are known tentatively to associate with the objective being referred to. Subsequently, the inferred pharmacophore model can be utilized to look through accumulate data sets (libraries) consequently evaluating for potential medication competitors that might be of interest.

Distinguishing three-dimensional pharmacophore is somewhat simple for inflexible cyclic designs. With additional adaptable designs, it isn't the case clear in light of the fact that the particle can embrace an enormous quantity of shapes or compliances which place the significant restricting gatherings in various positions comparative with one another. Regularly only one of these compliances is perceived and limited by the limiting site. The active conformation is the name given to this conformation.

Knowing the active conformation is necessary for locating the 3D pharmacophore. There are different manners by which this may be finished. Inflexible analogs of the adaptable compound could be incorporated and tried to see whether action is held. Alternately, One possibility might be to crystallize the target while the chemical is bonded to the binding site.. After that, Using X-ray crystallography, one could determine the active conformation of the bound ligand and the complex's structure.

Optimization of Lead

Lead enhancement is the composite, non-straight course of refinement the substance design of an affirmed hit to further develop its medication qualities determined to create a preclinical medication competitor. This stage regularly addresses the bottleneck of a medication disclosure program.

When the significant restricting gatherings and lead compound or pharmacophore have been recognized it is feasible to incorporate analogs that include the equivalent pharmacophore. Not extremely many lead compounds are great. The majority are expected to have significant side effects, slow activity, and reduced selectivity. They may likewise be challenging to blend, so there is a benefit in tracking down analogs with further developed properties.

The accompanying methodologies are utilized to improve the cooperations of a medication with its objective to acquire higher movement and selectivity.

- Variety of substituents Augmentation of the design
- Expanding and contracting the chain
- Ring development/constriction
- Ring varieties &Ring combinations
- Isosteres and Bioisosteres
- Rearrangements of the design

CONCLUSION

In current review an original sequence of coumarin sulfonamides and amides subordinates were viewed as the most strong subsidiary, which showed great antiproliferative exercises separately. Additionally, examining consequences of the cell cycle examination disentangled that compound captured the cell cycle chiefly in the G0/G1 stage. Compounds isn't just with huge anticancer action, yet additionally had promising pharmacokinetic properties. This study present data is useful for the plan and combination of novel coumarin subordinates medication applicants as antitumor potential.

REFERENCES

1. Momna Hejmadi. Introduction to cancer biology. Ventus Publishing ApS, 2010; 6-13.
2. Cance[Online].Availablefrom:http://www.elmhurst. edu/~chm/vchembook/655cancer.html [Accessed on February 21, 2012].
3. B. Ganesh, Sanjay D. Talole, Rajesh Dikshit, A case–control study on diet and colorectal cancer from Mumbai, India. Cancer Epidemiology, 2009; 33: 189–93.
4. Rajaraman Swaminathan, Ramanujam Selvakumaran, Pulikattil Okkuru Esmy, P. Sampath, Jacques Ferlay, Vinoda Jissa, Viswanathan Shanta, Cancer pattern and survival in a rural district in South India. Cancer Epidemiology, 2009; 33: 325–31.
5. J. Cardoso, J. Boer, H. Morreau, R. Fodde, Expression and genomic profiling of colorectal cancer. Biochimica et Biophysica Acta, 2007; 103–37.
6. H.E. Blum, Colorectal Cancer: Future Population Screening for Early Colorectal Cancer. Eur. J. cancer, 1995; 31A: 1369-72.
7. Suzanne Hector, Jochen H.M. Prehn, Apoptosis signaling proteins as prognostic biomarkers in colorectal cancer: A review. Biochimica et Biophysica Acta, 2009; 117–29.
8. Laura Asnaghi, Paola Bruno, Marcella Priulla, Angelo Nicolin, mTOR: a protein kinase switching between life and death. Pharmacological Research, 2004; 50: 545– 49.
9. David A. Guertin and David M. Sabatini, Defining the Role of mTOR in Cancer. Cancer Cell, 2007; 12: 9-22.
10. JB Easton and PJ Houghton, mTOR and cancer therapy. Oncogene, 2006; 25: 6436– 46.
11. Carlos Garcia-Echeverria, Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment. Bioorg. & Med. Chem. Lett., 2010; 20: 4308-12.
12. mTOR pathway [Online].Available from: www.abcam.com [Accessed on February 21, 2012].
13. Margit Rosner, Michaela Hanneder, Nicol Siegel, Alessandro Valli, Christiane Fuchs, Markus Hengstschlager, The mTOR pathway and its role in human genetic diseases. Mut. Res., 2008; 659: 284-92.
14. Dos D Sarbassov, Siraj M Ali and David M Sabatini, Growing roles for the mTOR pathway.

Current Opinion in Cell Biology, 2005; 17: 596–603.
15. Jie Chen, Yimin Fang, A novel pathway regulating the mammalian target of rapamycin (mTOR) signaling. Biochemical Pharmacology, 2002; 64: 1071-77.
16. Koji Ogata and Hideaki Umeyama, An automatic homology modeling method consisting of database searches and simulated annealing. J. Mol. Graphics Mod., 2000; 18: 258–72.
17. Anthony Ivetac and J. Andrew McCammon. A Molecular Dynamics EnsembleBased Approach for the Mapping of Druggable Binding Sites. In: Riccardo Baron, editor. Computational drug discovery and design, methods in molecular biology. USA: Humana Press, 2012; 3-9.
18. Daniel Seeliger, Bert L. de Groot, Ligand docking and binding site analysis with PyMOL and Autodock/Vina. J. Comp. Aided Mol. Des., 2010; 24: 417-22.
19. Povl Krogsgaard-Larsen, Tommy Liljefors and Ulf Madsen. Textbook of Drug Design and Discovery. 3rd ed. London and Newyork: Taylor & Francis, 2005.
20. Lipinski C.A, Lombardo.F, Dominy B.W and Feeney P.J. Experimental and Computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev., 1997; 23(1-3): 3-25.
21. Kitchen DB, Decornez H, Furr JR, Bajorath J, Docking and scoring in virtual screening for drug discovery: methods and applications. Nature reviews, Drug discovery, 2004; 3(11): 935-49.
22. Lengauer T, Rarey M, Computational methods for biomolecular docking. Curr. Opin. Struct. Biol., 1996; 6(3): 402-6.
23. Solomon V R, Lee H, Quinoline as a priviledged scaffold in cancer drug discovery. Curr. Med. Chem., 2011; 18(10): 1488-508.
24. Karunakar Tanneeru, Lalitha Guruprasad, Ligand-based 3-D pharmacophore generation and molecular docking of mTOR kinase inhibitors. J. Mol. Model., 2011.
25. Drug design [Online]. Available from: www.celgene.com/research/drug_discovery_and _development.aspx [Accessed on February 14, 2012].
26. Drug design [Online]. Available from: www.scfbio_iitd.res.in/tutorial/drugdiscovery.htm [Accessed on February 22, 2012].
27. Catalyst, version 4.11; Accelrys Inc: San Diego, CA 92121, USA, 2010.
28. Cerius2, version 4.11; Accelrys Inc: San Diego, CA 92121, USA, 2010.
29. Catalyst [Online]. Available from: http://accelrys.com/products/datasheets/pharmacophore_modelling.pdf [Accessed on January 12, 2012].
30. Glide version 9.1, Schrodinger, L.L.C., New York, 2010.
31. Graham L.Patrick. An introduction to medicinal chemistry, 4th ed. Oxford university press: 2008.p.683-84. 32. Molecular properties [Online]. Available from: www.molinspiration.com [Accessed on February 29,2012]
32. A.I. Vogel, A.R. Tatchell, B.S. Furnis, A.J. Hannaford, P.W.G. Smith. Vogel's textbook of practical organic chemistry. 5th ed. New Delhi: Prentice Hall, 2007; 1187.
33. Hiren M. Marvaniya, Palak K. Parikh and Dhrubo Jyoti Sen, Synthesis and in-vitro screening of 3,4-dihydropyrimidin-2(1H)-one derivatives for antihypertensive and calcium channel blocking activity. J. App. Pharm. Sci., 2011; 1(5): 109-13.
34. Mostafa M. Ghorab, Fatma A. Ragab, Mostafa M. Hamed, Design, synthesis and anticancer evaluation of novel tetrahydroquinoline derivatives containing sulfonamide moiety. European Journal of Medicinal Chemistry, 2009; 44: 4211–17.
35. Yue-Ling Zhao, Yeh-Long Chen, Feng-Shuo Chang, Cherng-Chyi Tzeng, Synthesis and cytotoxic evaluation of certain 4-anilino-2-phenylquinoline derivatives. Eur. J. Med. Chem., 2005; 40: 792–97.
36. Afshin Zarghi, Razieh Ghodsi, Design, synthesis, and biological evaluation of ketoprofen analogs as potent cyclooxygenase-2 inhibitors. Bioorg. Med. Chem., 2010; 18: 5855–60.
37. K.D. Thomas, Airody Vasudeva Adhikari, Sandeep Telkar, Imran H. Chowdhury, Riaz Mahmood, Nishith K. Pal, Guru Row, E. Sumesh, Design, synthesis and docking studies of new quinoline-3-carbohydrazide derivatives as antitubercular agents. European Journal of Medicinal Chemistry, 2011; 46: 5283-92.
38. Gurdeep R. Chatwal, Sham K. Anand. Instrumental methods of Chemical Analysis. 5th ed. Himalayan Publishing House, 2005; 2: 196-226.
39. Sharma B.K. Instrumental methods of Chemical Analysis. Meerut: Goel Publishing House, 1994.
40. Skoog, West Holler, Crouch. Fundamental of Analytical Chemistry. 8th ed. Singapore: Thomson Books/Cole, 2008; 710-40.